Synairgen raises £87m to bring Covid-19 treatment to market
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
EquityABBs-Block Trades

Synairgen raises £87m to bring Covid-19 treatment to market

Synairgen_2_PA_575_375

UK biotech firm Synairgen has finished the second leg of an £87m capital increase to fund the next round of clinical trials of a treatment designed to alleviate the respiratory symptoms of Covid-19.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article